While SRC-3 (also called as AIB1, or RAC3/ACTR/TRAM-1/NCOA3) was originally identified by its frequent amplification in breast and ovarian cancers and subsequently demonstrated it is homologous to SRC-1 and SRC-2. Here, NCOA3 is linked to ovarian cancer.